China News Service, November 13th (Reporter Chen Jing) In China, lung cancer is the malignant tumor with the highest incidence, and there are many cases of lung cancer each year.

Professor Han Baohui, dean of the China Lung Cancer Institute and director of the Department of Respiratory Medicine of Shanghai Chest Hospital, said in an interview on the 13th: "In the past, lung cancer patients often lived for less than a year, but now many patients have survived with new treatments. Eight years or even ten years; in the future, we are confident that lung cancer will become a'chronic disease'. In the field of lung cancer immunotherapy, Chinese experts are doing some research."

  Smoking is the leading risk factor for small cell lung cancer.

The expert bluntly said that for many years, small cell lung cancer has always been a difficult point in the treatment of lung cancer.

Professor Han Baohui bluntly said that the treatment of small cell lung cancer has not made breakthrough progress in nearly 40 years, and the only clinical treatment method is radiotherapy and chemotherapy.

Although patients with small cell lung cancer are sensitive to radiotherapy and chemotherapy, they are prone to relapse after radiotherapy and chemotherapy, and the treatment effect after recurrence is very poor. The median overall survival of patients is often less than 1 year.

Professor Han Baohui said that the emergence of immunotherapy has brought a new chapter in the treatment of small cell lung cancer and brought new hope for treatment.

He appealed: "For new treatment methods, more emphasis should be placed on standardized treatment."

  Immunotherapy uses a series of immune-related treatment methods to destroy tumor cells with the help of the body's own immune system. It has the characteristics of improving the ability of the immune system to recognize and eliminate tumor cells and having a slight impact on normal tissues.

The expert pointed out that combined immunotherapy is a more promising treatment strategy for small cell lung cancer.

  "Standardized diagnosis and treatment of lung cancer is a problem that we need to take seriously and solve. Improving standardized diagnosis and treatment should include not over-diagnosing, not missing diagnosis, or missing treatment." Professor Han Baohui said.

  During the interview, the reporter learned that dozens of experts from the field of lung cancer gathered at the national kick-off meeting of "Knowing and Breathing-A New Path for Lung Cancer Immunotherapy" jointly sponsored by China Lung Cancer Institute and China Health Promotion Foundation. , To share the latest progress in lung cancer immunotherapy and its standardized diagnosis and treatment to improve the level of lung cancer diagnosis and treatment.

The China Lung Cancer Institute, established in November 2019, brings together many professionals in the field of lung cancer in China, formulates and updates lung-related diagnosis and treatment specifications, and is committed to training specialists and grassroots doctors; creating a platform for online and offline business exchanges and continuing education .

  Professor Han Baohui told reporters that many clinical studies in the field of lung cancer in China currently reflect international standards. Related research led by Professor Wang Changli from Tianjin Cancer Hospital reflects the profound thinking of Chinese experts. He believes that China will have a lot of unique research in the field of immunotherapy. The expert said that China has huge patient resources and clinical research potential, as well as well-trained clinical experts. He hopes to not only do domestic research, but also strengthen international multi-center cooperative research to jointly improve the long-term survival of lung cancer patients. (Finish)